Is Alto Neuroscience, Inc. (ANRO) overvalued? · $60.1M cap
Alto Neuroscience, Inc. (ANRO) is a biotechnology company listed on US.
This page asks whether Alto Neuroscience, Inc. (ANRO) looks expensive on cached numbers — not a short thesis.
No cached income statement for ANRO, so there is no earnings base to call rich or cheap.
ANRO currently screens at market cap $60.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ANRO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ANRO stock page for the full model, not this heading.
Not investment advice.